This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
As part of the collaboration, Dyno will be responsible for the design of the novel AAV capsids, while Roche and its Spark Therapeutics division will develop the capsids in preclinical studies, ... This new partnership represents Dyno’s largest
Also in the running is SPK-8011 from Spark Therapeutics – although this contender suffered a setback in 2018 after two patients treated with the therapy developed immune reactions.
Pens another gene therapy deal following takeover of Spark Therapeutics. Fresh from its drawn-out takeover of Spark Therapeutics, Roche has signed another gene therapy deal, licensing Sarepta’s Duchenne muscular
Comes on the heels of CMA green light. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following ... with and into Spark without a vote or meeting of Spark’s
Roche first announced deal in February. Its a happy day for Roche, as it clears one of the hurdles in the way of its $4.3 acquisition of Spark Therapeutics, after ... Adding Spark’s gene therapies SPK-8011 and earlier-stage follow-up SPK-8061 for
data to come in on all the near-term candidates – which also includes Spark Therapeutics’ SPK-8011 – to see which has the best clinical profile. ... Spark suffered a setback last year after two patients treated with SPK-8011 developed immune
More from news
Approximately 17 fully matching, plus 35 partially matching documents found.
Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining
Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...